Information  X 
Enter a valid email address

EPIC/TIDM matching '0QQ6'

Date
Time Source
Company
Announcement
19 Sep 2020 3:20 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
18 Sep 2020 2:20 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
  6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
17 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
16 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
11 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis
10 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
09 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
08 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients
07 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
04 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems
03 Sep 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020
01 Sep 2020 8:30 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS
28 Aug 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test
19 Aug 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19
17 Aug 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
10 Aug 2020 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis
06 Aug 2020 9:00 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
05 Aug 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients
03 Aug 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
31 Jul 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
29 Jul 2020 4:45 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
23 Jul 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) First half of the year with 1%1 growth at constant exchange rates, significant impact of COVID-19 pandemic
22 Jul 2020 5:00 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
14 Jul 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
13 Jul 2020 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
29 Jun 2020 5:45 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
  2:00 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A
  10:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s ENSPRYNG® (satralizumab) approved in Japan for adults and children with neuromyelitis optica spectrum disorder
26 Jun 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm
19 Jun 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
18 Jun 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
13 Jun 2020 7:30 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
12 Jun 2020 9:15 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA)
04 Jun 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response
02 Jun 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
29 May 2020 11:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer
28 May 2020 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
27 May 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
22 May 2020 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder
19 May 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer
15 May 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches new blood gas digital solution designed to improve patient care
14 May 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO
11 May 2020 1:10 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Changes to the Roche Enlarged Corporate Executive Committee
07 May 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care
03 May 2020 3:15 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
28 Apr 2020 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA)
22 Apr 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) First quarter with 2% growth in Swiss francs, 7%[1] at constant exchange rates
21 Apr 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer
20 Apr 2020 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t